Showing results (41-50 of 307) with videos related to
Sort By:
Pageof 31
Bone|June 14, 2020
The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosisPolyzois Makras, Socrates E Papapoulos, Stergios A Polyzos, et al.Bone|July 1, 2020
Zoledronate decreases CTLA-4 in vivo and in vitro independently of its action on bone resorptionAndrea Giusti, Dario Camellino, Daniele Saverino, et al.Cytokine & Growth Factor Reviews|May 5, 2005
SOST/sclerostin, an osteocyte-derived negative regulator of bone formationRutger L van Bezooijen, Peter ten Dijke, Socrates E Papapoulos, et al.Journal of Clinical Medicine|September 28, 2023
Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of DenosumabAthanasios D Anastasilakis, Polyzois Makras, Julien Paccou, et al.Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|September 28, 2004
Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal womenSocrates E Papapoulos, Sara A Quandt, Uri A Liberman, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 22, 2019
Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical TrialAthanasios D Anastasilakis, Socrates E Papapoulos, Stergios A Polyzos, et al.Journal of Cellular Biochemistry|October 24, 2007
Is HMGB1 an osteocyte alarmin?Joseph P Bidwell, Jieping Yang, Alexander G RoblingThe Journal of Biological Chemistry|November 8, 2002
Peroxisome proliferator-activated receptor gamma (PPARgamma ) as a molecular target for the soy phytoestrogen genisteinZhi-Chao Dang, Valérie Audinot, Socrates E Papapoulos, et al.Calcified Tissue International|February 10, 2011
No effect of rosuvastatin in the zoledronate-induced acute-phase responsePolyzois Makras, Athanasios D Anastasilakis, Stergios A Polyzos, et al.Bone|September 22, 2009
Nmp4/CIZ: road block at the intersection of PTH and loadPaul Childress, Alexander G Robling, Joseph P BidwellPageof 31